多发性-话题@MedSci

#多发性#

905篇内容 | 2965人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1890158, encodeId=7e3f189015801, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：Otub1/c-Maf轴可能是多发性骨髓瘤的潜在治疗靶点, objectType=article, longId=200226, objectId=13a020022656, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a020022656, replyNumber=0, likeNumber=66, createdTime=2021-05-26, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a020022656, moduleTitle=Blood：Otub1/c-Maf轴可能是多发性骨髓瘤的潜在治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a020022656)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890236, encodeId=b1c8189023693, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Acta Neuropathologica: 多发性硬化皮质灰质坏死信号的神经元特异性激活, objectType=article, longId=209126, objectId=a03d2091263c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a03d2091263c, replyNumber=0, likeNumber=107, createdTime=2021-08-16, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a03d2091263c, moduleTitle=Acta Neuropathologica: 多发性硬化皮质灰质坏死信号的神经元特异性激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a03d2091263c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890189, encodeId=6a4318901899d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JNNP：使用系统方法选择许可药物用于治疗进展性多发性硬化症, objectType=article, longId=203772, objectId=2f43203e727b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f43203e727b, replyNumber=0, likeNumber=71, createdTime=2020-11-27, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f43203e727b, moduleTitle=JNNP：使用系统方法选择许可药物用于治疗进展性多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f43203e727b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890183, encodeId=e3bc1890183c7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, objectType=article, longId=203482, objectId=6ec6203482bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec6203482bb, replyNumber=0, likeNumber=70, createdTime=2021-04-07, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec6203482bb, moduleTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ec6203482bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890172, encodeId=d71718901e29c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Acta Neuropathologica: 多发性硬化症再髓鞘化受损的阶段依赖性原因, objectType=article, longId=202333, objectId=0ade202333e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ade202333e2, replyNumber=0, likeNumber=62, createdTime=2021-04-09, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ade202333e2, moduleTitle=Acta Neuropathologica: 多发性硬化症再髓鞘化受损的阶段依赖性原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ade202333e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890184, encodeId=5526189018470, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：多发性骨髓瘤克隆进化和扩散的特征, objectType=article, longId=203510, objectId=b46920351040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b46920351040, replyNumber=0, likeNumber=0, createdTime=2021-04-11, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b46920351040, moduleTitle=Blood：多发性骨髓瘤克隆进化和扩散的特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b46920351040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890182, encodeId=710618901826d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者, objectType=article, longId=203388, objectId=15ae203388b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ae203388b5, replyNumber=0, likeNumber=61, createdTime=2020-11-24, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ae203388b5, moduleTitle=Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ae203388b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890141, encodeId=f07818901411f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=69, createdTime=2020-12-18, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890156, encodeId=b6c81890156f4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, objectType=article, longId=200078, objectId=465a2000e861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=465a2000e861, replyNumber=0, likeNumber=64, createdTime=2020-09-10, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=465a2000e861, moduleTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=465a2000e861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890148, encodeId=88ef1890148a2, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险, objectType=article, longId=199174, objectId=50731991e4c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50731991e4c8, replyNumber=0, likeNumber=90, createdTime=2021-01-06, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50731991e4c8, moduleTitle=JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50731991e4c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890175, encodeId=73ea18901e52e, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=第八届全国血液肿瘤学术大会，多发性骨髓瘤国内全新治疗策略，看邱录贵教授给您一文理清, objectType=article, longId=202661, objectId=f365202661a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f365202661a6, replyNumber=0, likeNumber=68, createdTime=2021-05-13, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f365202661a6, moduleTitle=第八届全国血液肿瘤学术大会，多发性骨髓瘤国内全新治疗策略，看邱录贵教授给您一文理清, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f365202661a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890192, encodeId=c7de18901921c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, objectType=article, longId=204234, objectId=b3d02042345e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d02042345e, replyNumber=0, likeNumber=80, createdTime=2021-08-09, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d02042345e, moduleTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d02042345e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890123, encodeId=c18b1890123d1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=强生的CAR-T疗法JNJ-4528用于多发性骨髓瘤：86%的患者获得完全缓解, objectType=article, longId=194235, objectId=88cf19423508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88cf19423508, replyNumber=0, likeNumber=74, createdTime=2021-05-01, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88cf19423508, moduleTitle=强生的CAR-T疗法JNJ-4528用于多发性骨髓瘤：86%的患者获得完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88cf19423508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890241, encodeId=de831890241a1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带, objectType=article, longId=210168, objectId=59d1210168f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59d1210168f1, replyNumber=0, likeNumber=67, createdTime=2021-05-25, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59d1210168f1, moduleTitle=JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59d1210168f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=鼻内给予抗炎药治疗有望缓解多发性硬化症的进展, objectType=article, longId=202346, objectId=511e20234669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=511e20234669, replyNumber=0, likeNumber=83, createdTime=2021-03-28, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=511e20234669, moduleTitle=鼻内给予抗炎药治疗有望缓解多发性硬化症的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=511e20234669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890119, encodeId=2c2318901190f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, objectType=article, longId=193523, objectId=093019352369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=093019352369, replyNumber=0, likeNumber=73, createdTime=2020-12-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=093019352369, moduleTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=093019352369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890224, encodeId=87351890224dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=80, createdTime=2021-10-11, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890199, encodeId=5ebc18901994d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=87, createdTime=2021-08-07, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890132, encodeId=3ae818901328a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JCEM：2型糖尿病相关的多发性神经病患者疼痛与血管事件和死亡率相关, objectType=article, longId=196451, objectId=659b196451c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b196451c1, replyNumber=0, likeNumber=63, createdTime=2020-12-10, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b196451c1, moduleTitle=JCEM：2型糖尿病相关的多发性神经病患者疼痛与血管事件和死亡率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=659b196451c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890108, encodeId=b6b618901089a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=PNAS：熊果酸逆转多发性硬化症中的神经元损伤, objectType=article, longId=192085, objectId=143c192085fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=143c192085fb, replyNumber=0, likeNumber=129, createdTime=2020-12-08, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=143c192085fb, moduleTitle=PNAS：熊果酸逆转多发性硬化症中的神经元损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=143c192085fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性

2020-05-29

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：Otub1/c-Maf轴可能是多发性骨髓瘤的潜在治疗靶点

2021-05-26

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Acta Neuropathologica: 多发性硬化皮质灰质坏死信号的神经元特异性激活

2021-08-16

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JNNP：使用系统方法选择许可药物用于治疗进展性多发性硬化症

2020-11-27

jml2009 (审核中...)

前往app查看评论内容

#多发性#

The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期

2021-04-07

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Acta Neuropathologica: 多发性硬化症再髓鞘化受损的阶段依赖性原因

2021-04-09

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：多发性骨髓瘤克隆进化和扩散的特征

2021-04-11

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者

2020-11-24

jml2009 (审核中...)

前往app查看评论内容

#多发性#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2020-12-18

jml2009 (审核中...)

前往app查看评论内容

#多发性#

FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请

2020-09-10

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JAMA Neurol：继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险

2021-01-06

jml2009 (审核中...)

前往app查看评论内容

#多发性#

第八届全国血液肿瘤学术大会，多发性骨髓瘤国内全新治疗策略，看邱录贵教授给您一文理清

2021-05-13

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗

2021-08-09

jml2009 (审核中...)

前往app查看评论内容

#多发性#

强生的CAR-T疗法JNJ-4528用于多发性骨髓瘤：86%的患者获得完全缓解

2021-05-01

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带

2021-05-25

jml2009 (审核中...)

前往app查看评论内容

#多发性#

鼻内给予抗炎药治疗有望缓解多发性硬化症的进展

2021-03-28

jml2009 (审核中...)

前往app查看评论内容

#多发性#

FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤

2020-12-15

jml2009 (审核中...)

前往app查看评论内容

#多发性#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-10-11

jml2009 (审核中...)

前往app查看评论内容

#多发性#

FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤

2021-08-07

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JCEM：2型糖尿病相关的多发性神经病患者疼痛与血管事件和死亡率相关

2020-12-10

jml2009 (审核中...)

前往app查看评论内容

#多发性#

PNAS：熊果酸逆转多发性硬化症中的神经元损伤

2020-12-08

科室
- - 订阅+
  - 更多科室
工具
服务